Who Paid My Doc
Christopher Ray
Neurology Saint Louis, MO Medical Doctor
NPI 1881188985 CMS profile 5298521
4921 Parkview Pl, Div Neurology General, Ste 6C, Saint Louis, MO 63110
General payments
$353
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Christopher Ray of Saint Louis, MO is reported in the CMS Open Payments database as having received $353 across 5 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 30th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $150 | 1 | |
| 2024 | General | $37 | 1 | |
| 2023 | General | $20 | 1 | |
| 2022 | General | $146 | 2 |
Beside peers
- Christopher Ray
- Neurology median
- Middle half of Neurology
- National median
In program year 2025, general payments to Christopher Ray were reported at $150. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.
Show as a table
| Year | Christopher Ray | Neurology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $474 | $118–$2,177 | $163 |
| 2020 | $0 | $367 | $82–$2,309 | $114 |
| 2021 | $0 | $438 | $104–$2,547 | $132 |
| 2022 | $146 | $442 | $103–$2,388 | $149 |
| 2023 | $20 | $464 | $119–$2,312 | $160 |
| 2024 | $37 | $468 | $119–$2,323 | $164 |
| 2025 | $150 | $457 | $118–$2,344 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
417
Drug cost
$132,275
Branded share of claims
61.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Nurtec Odt Rimegepant Sulfate | Brand | 34 | $45,213 | |
| Ubrelvy Ubrogepant | Brand | 33 | $33,708 | |
| Emgality Pen Galcanezumab-Gnlm | Brand | 37 | $31,458 | |
| Ajovy Autoinjector Fremanezumab-Vfrm | Brand | 11 | $9,634 | |
| Ajovy Syringe Fremanezumab-Vfrm | Brand | 12 | $8,430 | |
| Propranolol Hcl Er Propranolol Hcl | Brand | 32 | $614 | |
| Duloxetine Hcl | Generic | 24 | $529 | |
| Rizatriptan Rizatriptan Benzoate | Brand | 38 | $433 | |
| Gabapentin | Generic | 16 | $401 | |
| Venlafaxine Hcl Er Venlafaxine Hcl | Brand | 22 | $336 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 24 billing codesPaid by Medicare
$52,812
Medicare patients
159
Services billed
5,509
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 57% | |
| Depression | 44% | |
| Chronic kidney disease | 36% | |
| Diabetes | 33% | |
| Ischemic heart disease | 31% | |
| Heart failure | 28% | |
| Atrial fibrillation | 28% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 11 | 5,155 | $25,690 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurology in Missouri
Related records
Neurology in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Neurology
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.